Uncategorized

FDA asks for more data on Lilly’s Foundayo to assess heart, liver risks

Published

on

The FDA is concerned that Eli Lilly’s newly approved obesity pill Foundayo might come with a risk for major cardiovascular events and liver damage, and has asked the company to provide data …

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version